In a significant move, the Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, has unveiled the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme (RPTUAS).
The scheme, which now offers incentives of up to Rs 1 crore per unit, marks a strategic initiative by the government to propel the industry towards excellence and competitiveness in the global arena.
Changes in the Scheme as in 2024
The revamped RPTUAS brings about several noteworthy changes to adapt to the evolving needs of the pharmaceutical landscape.
Firstly, the eligibility criteria have been broadened to encompass not just Micro, Small, and Medium Enterprises (MSMEs) but also any pharmaceutical manufacturing unit with a turnover of less than 500 crores.
Furthermore, the scheme now extends its support to a broader spectrum of technological upgrades, aligning with the revised Schedule-M and WHO-GMP standards, thus ensuring comprehensive assistance in enhancing pharmaceutical manufacturing standards across the board.
About the Scheme
RPTUAS seeks to uplift the technological capabilities of the pharmaceutical industry while ensuring strict adherence to global manufacturing standards. By introducing subsidies on a reimbursement basis, the scheme aims to incentivize pharmaceutical units to invest in upgrading their technological infrastructure.
Benefits of the Scheme
The revamped RPTUAS offers a myriad of benefits to the pharmaceutical industry and its stakeholders. Firstly, by broadening the eligibility criteria, the scheme supports smaller players in the industry, enabling them to achieve high-quality manufacturing standards and compete on a level playing field with larger counterparts. The introduction of a dynamic incentive structure based on turnover further incentivizes participation and investment in technological upgrades.
Moreover, the scheme’s integration with state government schemes allows for additional top-up assistance, maximizing support for the industry’s technology upgradation endeavors.
Data Insights
– Under the revamped RPTUAS scheme, pharmaceutical units with a turnover of less than Rs 50 crore are eligible for incentives of up to 20% of their investment in eligible activities.
– Units with a turnover ranging from Rs 250 crore to less than Rs 500 crore can avail incentives of up to 10% of their investment.
The revamped RPTUAS scheme epitomizes the government’s steadfast commitment to bolstering the technological prowess and global competitiveness of the pharmaceutical industry.
